GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
-4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| 1 |
Philip Morris
PM
|
$43M |
| 2 |
Amazon
AMZN
|
$24.3M |
| 3 |
Palantir
PLTR
|
$16.8M |
| 4 |
Yum China
YUMC
|
$14.4M |
| 5 |
Hims & Hers Health
HIMS
|
$10.9M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$40.6M |
| 2 |
NVIDIA
NVDA
|
$25.7M |
| 3 |
KE Holdings
BEKE
|
$14.3M |
| 4 |
Meta Platforms (Facebook)
META
|
$13.3M |
| 5 |
Coca-Cola
KO
|
$9.83M |
Sector Composition
| 1 | Technology | 42.51% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 7.8% |
| 5 | Consumer Staples | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
501
Day One Biopharmaceuticals
DAWN
$773M
| $20.5K | ﹤0.01% |
2,582
+465
| +22% | +$3.69K |
|
|
CSR
502
Centerspace
CSR
$1.01B
| $20.3K | ﹤0.01% |
314
+38
| +14% | +$2.46K |
|
503
Mineralys Therapeutics
MLYS
$2.31B
| $20.2K | ﹤0.01% |
1,274
+229
| +22% | +$3.64K |
|
|
DEA
504
Easterly Government Properties
DEA
$1.05B
| $20.2K | ﹤0.01% |
760
+54
| +8% | +$1.43K |
|
505
Evolus
EOLS
$495M
| $19.5K | ﹤0.01% |
1,621
+291
| +22% | +$3.5K |
|
|
AVDL
506
Avadel Pharmaceuticals
AVDL
$1.53B
| $19.3K | ﹤0.01% |
2,467
+444
| +22% | +$3.48K |
|
507
Replimune Group
REPL
$494M
| $19.2K | ﹤0.01% |
1,970
+354
| +22% | +$3.45K |
|
508
Xencor
XNCR
$610M
| $19.1K | ﹤0.01% |
1,791
+322
| +22% | +$3.43K |
|
509
Anavex Life Sciences
AVXL
$807M
| $18.6K | ﹤0.01% |
2,171
+391
| +22% | +$3.36K |
|
510
Intellia Therapeutics
NTLA
$1.29B
| $18.5K | ﹤0.01% |
2,608
+469
| +22% | +$3.34K |
|
|
AAT
511
American Assets Trust
AAT
$1.28B
| $18.4K | ﹤0.01% |
915
+36
| +4% | +$725 |
|
|
LENZ
512
LENZ Therapeutics
LENZ
$1.2B
| $18.1K | ﹤0.01% |
704
+127
| +22% | +$3.27K |
|
513
Praxis Precision Medicines
PRAX
$986M
| $18.1K | ﹤0.01% |
477
+86
| +22% | +$3.26K |
|
514
Fortrea Holdings
FTRE
$1.06B
| $17.3K | ﹤0.01% |
2,296
+413
| +22% | +$3.12K |
|
|
PDM
515
Piedmont Realty Trust, Inc.
PDM
$1.09B
| $17.2K | ﹤0.01% |
2,327
+91
| +4% | +$671 |
|
516
Prothena Corp
PRTA
$460M
| $17K | ﹤0.01% |
1,377
+247
| +22% | +$3.06K |
|
|
NXRT
517
NexPoint Residential Trust
NXRT
$879M
| $17K | ﹤0.01% |
429
+17
| +4% | +$672 |
|
518
Cogent Biosciences
COGT
$1.82B
| $16.9K | ﹤0.01% |
2,828
+509
| +22% | +$3.05K |
|
519
Arbutus Biopharma
ABUS
$805M
| $16.9K | ﹤0.01% |
4,852
+873
| +22% | +$3.05K |
|
520
AbCellera Biologics
ABCL
$1.26B
| $16.9K | ﹤0.01% |
7,563
+1,361
| +22% | +$3.04K |
|
|
SAFE
521
Safehold
SAFE
$1.17B
| $16.3K | ﹤0.01% |
871
+34
| +4% | +$636 |
|
522
ArriVent BioPharma
AVBP
$819M
| $16K | ﹤0.01% |
863
+155
| +22% | +$2.87K |
|
523
CureVac
CVAC
$1.21B
| $15.9K | ﹤0.01% |
5,744
+1,034
| +22% | +$2.86K |
|
524
Rocket Pharmaceuticals
RCKT
$354M
| $15.6K | ﹤0.01% |
2,333
+419
| +22% | +$2.8K |
|
525
AnaptysBio
ANAB
$613M
| $14.5K | ﹤0.01% |
779
+140
| +22% | +$2.6K |
|